Spero Therapeutics (SPRO) stock price, revenue, and financials

Spero Therapeutics market cap is $407 m, and annual revenue was $9.33 m in FY 2020

$407 M

SPRO Mkt cap, 29-Jul-2021

$9.3 M

Spero Therapeutics Revenue FY, 2020
Spero Therapeutics Net income (FY, 2020)-78.3 M
Spero Therapeutics EBIT (FY, 2020)-79.1 M
Spero Therapeutics Cash, 31-Dec-202085.2 M
Spero Therapeutics EV329.8 M
Get notified regarding key financial metrics and revenue changes at Spero TherapeuticsLearn more
Banner background

Spero Therapeutics Income Statement

Annual

USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

4.0m18.1m9.3m

R&D expense

32.9m33.9m65.8m67.0m

General and administrative expense

10.8m12.9m15.6m21.4m

Operating expense total

43.7m46.8m81.4m88.4m

EBIT

(41.7m)(42.8m)(63.2m)(79.1m)

EBIT margin, %

(1079%)(348%)(848%)

Interest expense

303.0k1.1m

Interest income

1.3m401.0k

Pre tax profit

(39.9m)(41.7m)(60.9m)(78.3m)

Net Income

(38.7m)(41.7m)(60.9m)(78.3m)

Spero Therapeutics Balance Sheet

Annual

USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

87.3m34.1m29.7m85.2m

Accounts Receivable

1.0m376.0k7.8m5.3m

Prepaid Expenses

1.8m7.5m4.8m6.1m

Current Assets

92.1m124.2m95.4m139.1m

PP&E

1.2m2.9m2.3m1.7m

Total Assets

93.5m129.0m106.1m153.5m

Accounts Payable

3.5m3.6m4.1m1.2m

Short-term debt

928.0k947.0k

Current Liabilities

8.2m12.3m26.7m14.3m

Long-term debt

4.9m7.1m

Total Debt

5.8m8.0m

Total Liabilities

8.5m13.2m31.5m21.4m

Common Stock

14.0k17.0k19.0k29.0k

Preferred Stock

3.0k

Additional Paid-in Capital

181.4m254.0m274.0m409.7m

Retained Earnings

(96.8m)(138.5m)(199.4m)(277.7m)

Total Equity

85.0m115.9m74.6m132.0m

Financial Leverage

1.1 x1.1 x1.4 x1.2 x

Spero Therapeutics Cash Flow

Annual

USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(39.9m)(41.7m)(60.9m)(78.3m)

Depreciation and Amortization

363.0k409.0k750.0k

Accounts Receivable

(707.0k)635.0k(7.4m)2.4m

Accounts Payable

2.3m84.0k564.0k(3.0m)

Cash From Operating Activities

(39.1m)(39.6m)(50.0m)(85.9m)

Purchases of PP&E

(27.0k)(2.4m)(314.0k)(157.0k)

Cash From Investing Activities

(27.0k)(83.2m)29.5m10.5m

Cash From Financing Activities

116.1m69.5m16.1m130.9m

Net Change in Cash

77.0m(53.3m)(4.3m)55.5m

Spero Therapeutics Ratios

USDQ3, 2017

Financial Leverage

-0.4 x

Spero Therapeutics Employee Rating

544 votes
Culture & Values
5
Work/Life Balance
4.9
Senior Management
4.9
Salary & Benefits
4.5
Career Opportunities
4.8
Source